Key result
During a 2-year follow-up of patients with tachyarrhythmias receiving antiarrhythmic therapy, 25 patients (5.5%) died, primarily from pump failure or noncardiac causes, with no cardiac deaths in the paroxysmal atrial fibrillation group.
Population
455 registered patients with tachyarrhythmias in Japan, including paroxysmal atrial fibrillation, sustained…
Design
Cohort
Follow-up
2 years
Authors
Loading...
May support antiarrhythmic safety in tachyarrhythmias; hypothesis-generating and leaves open need for randomized confirmation.
Observational (n=455)
Yes
In a Japanese cohort, long-term antiarrhythmic therapy showed a shift away from slow kinetic Na channel blockers for ventricular tachycardia, aligning with post-CAST evidence, while transition to chronic AF was notably absent in patients on calcium antagonists.
Katoh et al. (2001) conducted an observational in Tachyarrhythmias (paroxysmal atrial fibrillation, sustained ventricular tachycardia, nonsustained ventricular tachycardia) (n=455). Antiarrhythmic drug therapy was evaluated on 2-year prognosis (death, complications, and transition to chronic atrial fibrillation). During a 2-year follow-up of patients with tachyarrhythmias receiving antiarrhythmic therapy, 25 patients (5.5%) died, primarily from pump failure or noncardiac causes, with no cardiac deaths in the paroxysmal atrial fibrillation group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: